| Literature DB >> 23228390 |
Kanta Fujimoto1, Yoshiyuki Hamamoto, Sachiko Honjo, Yukiko Kawasaki, Kanako Mori, Hisato Tatsuoka, Atsuko Matsuoka, Yoshiharu Wada, Hiroki Ikeda, Jun Fujikawa, Hiroyuki Koshiyama.
Abstract
We retrospectively examined the frequency of bladder cancer in Japanese patients with type 2 diabetes in relation to use of pioglitazone. Among a total of 663 patients identified to be taking pioglitazone, 9 had bladder cancer (1.36%). Overall the hazard ratio of 1.75 [95% CI: 0.89-3.45] for pioglitazone for bladder cancer was not significant. However the prevalence of bladder cancer was 2.10% in patients taking pioglitazone for less than 24 months which was significant increased (HR 2.73 [95% CI: 1.11-6.72]).Entities:
Mesh：
Substances：
Year: 2012 PMID： 23228390 DOI： 10.1016/j.diabres.2012.11.013
Source DB: PubMed Journal: Diabetes Res Clin Pract ISSN： 0168-8227 Impact factor: 5.602